Cardiac amyloidosis: where are we today? (Q38528406)

3 September 2017

1 reference

title

Cardiac amyloidosis: where are we today? (English)

1 reference

3 September 2017

K S Patel

1

1 reference

3 September 2017

P N Hawkins

series ordinal

2

1 reference

3 September 2017

language of work or name

English

0 references

publication date

16 June 2015

1 reference

Journal of Internal Medicine

3 September 2017

published in

1 reference

3 September 2017

volume

278

1 reference

3 September 2017

issue

2

1 reference

3 September 2017

page(s)

126-144

1 reference

Systemic amyloidosis in England: an epidemiological study

3 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12383

Serum immunoglobulin free light-chain measurement in primary amyloidosis: prognostic value and correlations with clinical features

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12383

Transthyretin-derived amyloidosis: probably a common cause of lumbar spinal stenosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12383

Senile systemic amyloidosis: clinical features at presentation and outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12383

Revised transthyretin Ile 122 allele frequency in African-Americans

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12383

Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: the Transthyretin Amyloidosis Cardiac Study (TRACS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12383

Cardiac phenotype and clinical outcome of familial amyloid polyneuropathy associated with transthyretin alanine 60 variant.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12383

Biochemical and molecular genetic characterization of a new variant prealbumin associated with hereditary amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12383

Hereditary amyloid polyneuropathy in north west Ireland

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12383

A peculiar form of peripheral neuropathy; familiar atypical generalized amyloidosis with special involvement of the peripheral nerves

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12383

Diagnostic and prognostic value of low QRS voltages in cardiac AL amyloidosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12383

Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12383

The electrocardiographic features associated with cardiac amyloidosis of variant transthyretin isoleucine 122 type in Afro-Caribbean patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12383

Prevalence and prognostic value of conduction disturbances at the time of diagnosis of cardiac AL amyloidosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12383

Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12383

Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12383

A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12383

Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12383

Longitudinal left ventricular function for prediction of survival in systemic light-chain amyloidosis: incremental value compared with clinical and biochemical markers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12383

Relative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12383

Cardiovascular magnetic resonance in cardiac amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12383

Noncontrast T1 mapping for the diagnosis of cardiac amyloidosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12383

Native T1 mapping in transthyretin amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12383

Cardiovascular magnetic resonance measurement of myocardial extracellular volume in health and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12383

Quantification of myocardial extracellular volume fraction in systemic AL amyloidosis: an equilibrium contrast cardiovascular magnetic resonance study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12383

T1 mapping for myocardial extracellular volume measurement by CMR: bolus only versus primed infusion technique

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12383

Clinical diagnosis and typing of systemic amyloidosis in subcutaneous fat aspirates by mass spectrometry-based proteomics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12383

Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12383

Left ventricular systolic dysfunction precipitated by verapamil in cardiac amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12383

Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12383

Stringent patient selection improves outcomes in systemic light-chain amyloidosis after autologous stem cell transplantation in the upfront and relapsed setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12383

Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12383

Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12383

Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12383

Synergy of combined doxycycline/TUDCA treatment in lowering Transthyretin deposition and associated biomarkers: studies in FAP mouse models

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12383

Doxycycline plus tauroursodeoxycholic acid for transthyretin amyloidosis: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12383

Safety and efficacy of RNAi therapy for transthyretin amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12383

Antibody-mediated resolution of light chain-associated amyloid deposits.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12383

Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12383

Sustained pharmacological depletion of serum amyloid P component in patients with systemic amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12383

Antibodies to human serum amyloid P component eliminate visceral amyloid deposits

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12383

The conduction system in cardiac amyloidosis. Clinical and pathologic features of 23 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12383

ACCF/HRS/AHA/ASE/HFSA/SCAI/SCCT/SCMR 2013 appropriate use criteria for implantable cardioverter-defibrillators and cardiac resynchronization therapy: a report of the American College of Cardiology Foundation appropriate use criteria task force, Hear

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12383

Cardiac transplantation followed by dose-intensive melphalan and autologous stem-cell transplantation for light chain amyloidosis and heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12383

Clinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12383

High 99mTc-DPD myocardial uptake in a patient with apolipoprotein AI-related amyloidotic cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12383

Usefulness and limitations of 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy in the aetiological diagnosis of amyloidotic cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12383

Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12383

21 January 2018

Identifiers

DOI

10.1111/JOIM.12383

1 reference

3 September 2017

1 reference